|Fenretinide Lipid Matrix (Code C63482)|
|Terms & Properties|
Preferred Name: Fenretinide Lipid Matrix
Definition: An orally bioavailable powder formulation of a synthetic phenylretinamide analogue of retinol with potential chemopreventive and antineoplastic activities. Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types, including those of the colon, breast, prostate, and neuroblastoma. Independent of RAR activation, this agent also modulates gene expression that leads to ceramide-induced, caspase-independent programmed cell death (PCD) via effectors such as ganglioside GD3 and reactive oxygen species (ROS). Compared to the capsule form, the powder contains a mixture of wheat flour, fats, and sugar that may contribute to the enhanced bioavailability of fenretinide.
NCI-GLOSS Definition: A powdered form of fenretinide that is being studied in the treatment of neuroblastoma. It may be used by the body more easily than the pill form. Fenretinide may cause ceramide (a wax-like substance) to build up in tumor cells and kill them. It is a type of retinoid, which are substances related to vitamin A.
Display Name: Fenretinide Lipid Matrix
Label: Fenretinide Lipid Matrix
NCI Metathesaurus Link: C1831747 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
|Fenretinide Lipid Matrix|
External Source Codes:
|PDQ Closed Trial Search ID||468556|
|PDQ Open Trial Search ID||468556 (check for NCI PDQ open clinical trial info)|
|Name||Value (qualifiers indented underneath)|
Additional Concept Data:
|Defined Fully by Roles: No|